COLL logo

Collegium Pharmaceutical (COLL) EBITDA

annual EBITDA:

$341.70M+$33.37M(+10.82%)
December 31, 2024

Summary

  • As of today (July 1, 2025), COLL annual EBITDA is $341.70 million, with the most recent change of +$33.37 million (+10.82%) on December 31, 2024.
  • During the last 3 years, COLL annual EBITDA has risen by +$255.15 million (+294.77%).
  • COLL annual EBITDA is now at all-time high.

Performance

1-year change

+10.82%

3-year change

+294.77%

5-year change

+5498.14%

15-year change

+560.07%

COLL EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

90.94%
COLL annual EBITDA is higher than 90.94% of companies in Healthcare sector

Range

All-time high

$341.70M
COLL annual EBITDA is currently at an all-time high

3-year low

$86.56M
COLL annual EBITDA is currently +294.77% above its 3-year low

Earnings dates

Last annual earnings report date

Dec 31, 2024
COLL previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
COLL next annual earnings announcement has not yet been scheduled

OtherCOLLincome statement metrics

Annual revenue

$631.45M
COLL annual revenue is $631.45 million

annual net income

$69.19M
COLL annual net profit is $69.19 million

annual EBIT

$172.54M
COLL annual earnings before interest & taxes is $172.54 million

Annual EPS

$1.86
COLL annual earnings per share is $1.86

quarterly EBITDA:

$80.48M-$15.96M(-16.55%)
March 31, 2025

Summary

  • As of today (July 1, 2025), COLL quarterly EBITDA is $80.48 million, with the most recent change of -$15.96 million (-16.55%) on March 31, 2025.
  • Over the past year, COLL quarterly EBITDA has dropped by -$8.92 million (-9.98%).
  • COLL quarterly EBITDA is now -20.68% below its all-time high of $101.45 million, reached on December 31, 2023.

Performance

3-month change

-16.55%

1-year change

-9.98%

3-year change

+735.94%

5-year change

+410.44%

COLL quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

89.46%
COLL quarterly EBITDA is higher than 89.46% of companies in Healthcare sector

Range

All-time high

$101.45M
COLL quarterly EBITDA is currently -20.68% below its historical high of $101.45 million

3-year low

$42.15M
COLL quarterly EBITDA is currently +90.91% above its 3-year low

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
COLL previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 8, 2025
COLL next earnings announcement is scheduled for Aug 8, 2025

OtherCOLLincome statement metrics

Quarterly revenue

$177.76M
COLL quarterly revenue is $177.76 million

quarterly net income

$2.42M
COLL quarterly net profit is $2.42 million

quarterly EBIT

$23.91M
COLL quarterly earnings before interest & taxes is $23.91 million

Quarterly EPS

$0.07
COLL quarterly earnings per share is $0.07

TTM EBITDA:

$332.78M-$8.92M(-2.61%)
March 31, 2025

Summary

  • As of today (July 1, 2025), COLL TTM EBITDA is $332.78 million, with the most recent change of -$8.92 million (-2.61%) on March 31, 2025.
  • Over the past year, COLL TTM EBITDA has dropped by -$22.79 million (-6.41%).
  • COLL TTM EBITDA is now -6.97% below its all-time high of $357.70 million, reached on June 30, 2024.

Performance

3-month change

-2.61%

1-year change

-6.41%

3-year change

+476.2%

5-year change

+576.37%

COLL TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

90.22%
COLL TTM EBITDA is higher than 90.22% of companies in Healthcare sector

Range

All-time high

$357.70M
COLL TTM EBITDA is currently -6.97% below its historical high of $357.70 million

3-year low

$73.39M
COLL TTM EBITDA is currently +353.41% above its 3-year low

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
COLL previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 8, 2025
COLL next earnings announcement is scheduled for Aug 8, 2025

OtherCOLLincome statement metrics

TTM revenue

$664.28M
COLL TTM revenue is $664.28 million

TTM net income

$43.89M
COLL TTM net profit is $43.89 million

TTM EBIT

$142.49M
COLL TTM earnings before interest & taxes is $142.49 million

TTM EPS

$1.22
COLL TTM earnings per share is $1.22

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

annual EBITDA

$341.70M
COLL annual EBITDA is $341.70 million

annual net income

$69.19M
COLL annual net profit is $69.19 million

annual interest expense

$73.97M
COLL annual interest expense is $73.97 million

annual income tax

$29.38M
COLL annual income tax is $29.38 million

annual D&A

$169.16M
COLL annual depreciation & amortization is $169.16 million

COLL EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+10.8%-10.0%-6.4%
3 y3 years+294.8%+735.9%+476.2%
5 y5 years+5498.1%+410.4%+576.4%

COLL EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+294.8%-20.7%+90.9%-7.0%+353.4%
5 y5-yearat high+5498.1%-20.7%+576.2%-7.0%+576.4%
alltimeall timeat high+465.7%-20.7%+395.0%-7.0%+430.3%

COLL EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
$80.48M(-16.5%)
$332.78M(-2.6%)
Dec 2024
$341.70M(+10.8%)
$96.44M(+27.4%)
$341.70M(-1.4%)
Sep 2024
-
$75.72M(-5.5%)
$346.72M(-3.1%)
Jun 2024
-
$80.15M(-10.3%)
$357.70M(+0.6%)
Mar 2024
-
$89.39M(-11.9%)
$355.57M(+15.3%)
Dec 2023
$308.33M(+77.9%)
$101.45M(+17.0%)
$308.33M(+17.3%)
Sep 2023
-
$86.70M(+11.1%)
$262.76M(+12.0%)
Jun 2023
-
$78.02M(+85.1%)
$234.58M(+14.0%)
Mar 2023
-
$42.15M(-24.6%)
$205.83M(+18.8%)
Dec 2022
$173.31M(+100.2%)
$55.89M(-4.5%)
$173.31M(+72.4%)
Sep 2022
-
$58.52M(+18.8%)
$100.52M(+37.0%)
Jun 2022
-
$49.27M(+411.8%)
$73.39M(+27.1%)
Mar 2022
-
$9.63M(-157.0%)
$57.76M(-33.3%)
Dec 2021
$86.56M(-26.7%)
-$16.90M(-153.8%)
$86.56M(-36.1%)
Sep 2021
-
$31.40M(-6.6%)
$135.53M(-3.7%)
Jun 2021
-
$33.63M(-12.5%)
$140.75M(+0.1%)
Mar 2021
-
$38.43M(+19.8%)
$140.68M(+19.2%)
Dec 2020
$118.01M(-1964.4%)
$32.08M(-12.4%)
$118.01M(+34.4%)
Sep 2020
-
$36.62M(+9.1%)
$87.83M(+78.5%)
Jun 2020
-
$33.55M(+112.8%)
$49.20M(+227.4%)
Mar 2020
-
$15.77M(+732.4%)
$15.03M(-337.4%)
Dec 2019
-$6.33M
$1.89M(-194.1%)
-$6.33M(-133.1%)
Sep 2019
-
-$2.01M(+226.3%)
$19.10M(-55.6%)
DateAnnualQuarterlyTTM
Jun 2019
-
-$617.00K(-89.0%)
$43.04M(-37.9%)
Mar 2019
-
-$5.59M(-120.5%)
$69.26M(-24.6%)
Dec 2018
$91.91M(-223.7%)
$27.33M(+24.6%)
$91.91M(+94.3%)
Sep 2018
-
$21.93M(-14.4%)
$47.31M(+286.1%)
Jun 2018
-
$25.60M(+50.1%)
$12.25M(-135.7%)
Mar 2018
-
$17.06M(-198.7%)
-$34.34M(-53.8%)
Dec 2017
-$74.27M(-20.5%)
-$17.27M(+31.5%)
-$74.27M(-11.9%)
Sep 2017
-
-$13.13M(-37.5%)
-$84.28M(-13.4%)
Jun 2017
-
-$21.00M(-8.2%)
-$97.32M(-3.4%)
Mar 2017
-
-$22.87M(-16.2%)
-$100.75M(+7.8%)
Dec 2016
-$93.43M(+249.4%)
-$27.28M(+4.3%)
-$93.43M(+23.5%)
Sep 2016
-
-$26.17M(+7.1%)
-$75.63M(+28.9%)
Jun 2016
-
-$24.43M(+57.2%)
-$58.69M(+51.3%)
Mar 2016
-
-$15.54M(+63.9%)
-$38.79M(+45.1%)
Dec 2015
-$26.74M(+53.0%)
-$9.49M(+2.8%)
-$26.73M(+30.2%)
Sep 2015
-
-$9.23M(+103.7%)
-$20.53M(+15.6%)
Jun 2015
-
-$4.53M(+29.7%)
-$17.76M(+2.8%)
Mar 2015
-
-$3.49M(+6.5%)
-$17.27M(-1.2%)
Dec 2014
-$17.48M(+9.6%)
-$3.28M(-49.2%)
-$17.48M(+23.1%)
Sep 2014
-
-$6.46M(+59.8%)
-$14.20M(+83.5%)
Jun 2014
-
-$4.04M(+9.3%)
-$7.74M(+109.3%)
Mar 2014
-
-$3.70M
-$3.70M
Dec 2013
-$15.95M
-
-

FAQ

  • What is Collegium Pharmaceutical annual EBITDA?
  • What is the all time high annual EBITDA for Collegium Pharmaceutical?
  • What is Collegium Pharmaceutical annual EBITDA year-on-year change?
  • What is Collegium Pharmaceutical quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Collegium Pharmaceutical?
  • What is Collegium Pharmaceutical quarterly EBITDA year-on-year change?
  • What is Collegium Pharmaceutical TTM EBITDA?
  • What is the all time high TTM EBITDA for Collegium Pharmaceutical?
  • What is Collegium Pharmaceutical TTM EBITDA year-on-year change?

What is Collegium Pharmaceutical annual EBITDA?

The current annual EBITDA of COLL is $341.70M

What is the all time high annual EBITDA for Collegium Pharmaceutical?

Collegium Pharmaceutical all-time high annual EBITDA is $341.70M

What is Collegium Pharmaceutical annual EBITDA year-on-year change?

Over the past year, COLL annual EBITDA has changed by +$33.37M (+10.82%)

What is Collegium Pharmaceutical quarterly EBITDA?

The current quarterly EBITDA of COLL is $80.48M

What is the all time high quarterly EBITDA for Collegium Pharmaceutical?

Collegium Pharmaceutical all-time high quarterly EBITDA is $101.45M

What is Collegium Pharmaceutical quarterly EBITDA year-on-year change?

Over the past year, COLL quarterly EBITDA has changed by -$8.92M (-9.98%)

What is Collegium Pharmaceutical TTM EBITDA?

The current TTM EBITDA of COLL is $332.78M

What is the all time high TTM EBITDA for Collegium Pharmaceutical?

Collegium Pharmaceutical all-time high TTM EBITDA is $357.70M

What is Collegium Pharmaceutical TTM EBITDA year-on-year change?

Over the past year, COLL TTM EBITDA has changed by -$22.79M (-6.41%)
On this page